



6CX3  
Haddad

1600  
1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAR 06 2002

TECH CENTER 1600/2900

Applicant(s): Theill et al.

Serial No.: 09/854,864

Group Art Unit No.:

Filed: May 14, 2001

Examiner:

For: METHODS AND COMPOSITIONS OF MATTER  
CONCERNING APRIL/G70, BCMA, BLYS/AGP-3, AND  
TAC

P#8

Docket No.: A-686B

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 for consideration by the Examiner.

Applicant, by the undersigned attorney, certifies that each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Timothy J. Gaul  
Attorney for Applicants  
Registration No.: 33,111  
Phone: (805) 447-2688  
Date: Feb. 12, 2002

Please send all future correspondence to:  
U.S. Patent Operations/ TJG  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

February 12, 2002  
Date

Christina A. Gutierrez  
Signature